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Abstract 
Background: Peripheral inflammatory markers have been shown to predict outcomes in aging 
adults; however, the degree to which peripheral markers mirror the central nervous system 
milieu remains unknown. We investigated the association between plasma and CSF markers of 
inflammation, and further explored whether these markers independently predict CSF indicators 
of Alzheimer’s disease (AD) pathology or neuronal damage.  
Methods: Plasma and CSF samples were analyzed for inflammatory markers in a cohort of 
asymptomatic older adults enriched for a family history of AD (n=173). CSF samples were 
separately analyzed for markers of AD pathology (Aβ42, phosphorylated tau [p-tau],sAPP-β) or 
neuronal damage (total tau; neurofilament light chain [NFL]) (n=147). Analyses focused on 
markers in which detectable levels were obtained for at least 70% of both CSF and plasma 
(MIP-1β; MCP-1; IP-10; IL-8; IL-6). Separate linear models for each inflammatory analyte were 
conducted with CSF and plasma levels entered simultaneously as predictor variables and 
markers of AD pathology or neuronal damage as outcome measures.  
Results: Strong associations were noted between MIP-1β CSF and plasma levels (r=.55,), and 
modest associations were observed for remaining analytes. With respect to AD pathology, 
higher levels of IL-8 plasma and CSF, MIP-1β CSF, and IP-10 CSF were associated with higher 
levels of p-tau in separate models. Higher levels of IL-8 CSF were unexpectedly associated with 
higher levels of CSF Aβ1-42. Higher CSF sAPP-beta levels were associated with higher plasma 
inflammatory markers only (IL-8 and MCP-1). In terms of neuronal injury, higher levels of IL-8 
plasma and CSF, IP-10 CSF levels, and MIP-1β CSF levels were associated with higher levels 
of CSF total tau. Higher levels of IP-10 CSF and plasma, IL-6 plasma, and IL-8 CSF were 
associated with higher levels of NFL. Exploratory analyses indicated that CSF Aβ42 modifies 
the relationship between plasma inflammatory marker levels and CSF tau levels. 
Conclusions: Although modest associations were observed between plasma and CSF levels of 
inflammation in a cohort of asymptomatic aging adults, results suggest that both plasma and 
CSF inflammatory markers still independently relay integral information about AD pathology and 
neuronal damage. These findings add to a growing body of literature underscoring a complex 
relationship between systemic inflammation, central inflammation, and pathological outcomes. 
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1. Introduction 
Dysregulation of inflammatory cascades is considered to be a core pathological 
component of Alzheimer’s Disease (AD)1. Whereas basal levels of inflammation and pathogen-
specific activation of the immune system are clearly advantageous to the survival of our 
species, sustained inflammation has cytotoxic effects that may result in neuronal cell damage 
and acceleration of neurodegenerative processes2-5. Prior studies have linked CSF6-8 and 
blood9-11 levels of inflammation to clinical outcomes in Mild Cognitive Impairment (MCI), and 
epidemiological studies suggest that elevations in inflammatory markers may even be evident 
decades prior to manifestation of clinical symptoms12. These studies collectively highlight that 
dysregulated inflammatory process may play a pivotal role early in AD pathogenesis.  Despite 
these observations, however, disentangling the specific role and sequential impact of immune 
dysfunction on AD pathogenesis has proven to be challenging, and may stem in part from 
limitations in our understanding of the neurobiological significance of current immune 
biomarkers13, 14.  
Specifically, it is unclear how well the most frequently used method of assessing 
inflammation, i.e. peripheral (blood) inflammation, reflects or maps on to the central nervous 
system (CNS) immune milieu. Although several studies have measured CSF and blood markers 
of inflammation in tandem6, 7, 15, few have reported the strength of associations between the 
specimen types. One of the isolated studies to describe these associations in adults with AD 
showed a strong, positive correlation between CSF and plasma markers of interleukin-6 (IL-6), 
monocyte chemotactic protein-1 (MCP-1), and alpha(1)-antichymotrypsin (ACT)16; however, no 
study to our knowledge has systematically examined the association(s) between CSF and blood 
inflammation in healthy aging adults or preclinical AD. Moreover, the relative contribution of 
CNS versus peripheral inflammation to biomarker indicators of neuronal cell damage or AD 
pathology remains an unresolved question. A recent study by our colleagues demonstrated an 
association between higher levels of a CSF marker of inflammation (YKL-40) and higher levels 
of CSF neurofilament light chain and total tau in an aging cohort at risk for AD17; while this 
suggests that CNS inflammation may reflect evidence of neuronal damage, it does not pinpoint 
whether CNS inflammation is a more robust indicator of AD biomarkers and neuronal cell 
damage than peripheral inflammation. Development of novel in-vivo immune biomarkers for AD 
may be dependent upon a better understanding of the relationship between immune dysfunction 
and AD pathogenesis, which could establish earlier detection methods and new targets for 
future therapeutics.  
The goal of this study was to address a gap in the immune-AD field by examining two 
primary objectives: 1) to evaluate the relationship between CSF and plasma markers of 
inflammation in an asymptomatic, aging cohort at risk for AD; and 2) to determine the extent to 
which CSF and plasma inflammatory levels independently predict biomarkers of AD pathology 
and neuronal cell damage. Based on prior AD literature suggesting potential alterations in 
blood-CSF permeability in aging18, 19 as well as the corpus of neuroimmunology studies 
identifying direct and indirect mechanisms for communication between the CNS and periphery20, 
21, we anticipated that CSF and plasma levels would be correlated with each other; however, in 
an asymptomatic group, we hypothesized that the degree of association might represent only 
small to medium effects. In terms of plasma versus CSF inflammation and their relationships 
with markers of AD pathology and neuronal cell damage, we considered several competing 
hypotheses. First, if plasma inflammation reflects an indirect or possibly ‘diluted’ manifestation 
of CNS function, then controlling for CSF inflammation might result in a weak or nonexistent 
association between plasma inflammation and AD/neuronal biomarkers. In contrast, if plasma 
inflammation reflects distinct aspects of the CNS milieu, then we would expect associations with 
markers of AD pathology and neuronal cell damage to remain even when accounting for CSF 
inflammation. We elected to focus our analyses on inflammatory markers that were detectable 
in both CSF and plasma, thereby allowing for data-driven, head-to-head comparisons of the 
specimen types.  
2. Methods 
Study procedures were approved by the University of Wisconsin Health Sciences 
Institutional Review Board and were in accordance with U.S. federal regulations. All participants 
provided written informed consent. 
2.1 Participants 
Participants were asymptomatic middle-aged adults and older adults who were enrolled 
in the Wisconsin Alzheimer’s Disease Research Center (ADRC) clinical core, and a subset were 
also enrolled in the IMPACT cohort, the latter of which enriches for adults who have a family 
history of AD. The Wisconsin ADRC cohorts include well-characterized participants who 
undergo cognitive testing and neurological and physical exams, and are subsequently reviewed 
by a multidisciplinary consensus panel. In addition, inclusion criteria consisted of normal 
cognitive function determined by comprehensive neuropsychological evaluation and consensus 
review; negative history of psychiatric or neurological disease or untreated depression; and no 
history of head trauma. Please see prior publications for further description of this cohort17, 22. 
Participants were also required to have previously undergone lumbar puncture and blood draws 
for CSF and plasma assays, respectively, and were excluded from the analysis if their CSF and 
plasma blood draws occurred greater than 6 months apart. The final sample size for the study 
was 173 participants, although sample sizes for the individual objectives of the study varied 
based on assays conducted and available lab values for CSF and plasma (see section 2.3 
below; Table 1).  
 
[Table 1 Here] 
 
2.2. Genotyping: APOEε4 genotype was performed on a non-fasting blood sample collected at 
baseline, using standard PCR and DNA sequencing techniques. DNA extracted from whole 
blood was genotyped with use of a homogeneous Fluorescent Resonance Energy Transfer 
technology coupled to competitive allele specific PCR (LGC Genomics; Beverly, MA). 
Genotyping also was performed by NCRAD. There was 100% concordance for APOE genotype 
between these analyses. Participants were categorized using a binary variable as an APOEε4 
carrier or non-carrier. 
2.3. Plasma and CSF Collection and Analysis 
Plasma Collection: After collection, each blood sample was centrifuged at 2000× g for 
15 minutes at 4°C with the resultant plasma divided into 500 μL aliquots and stored at −80°C. 
CSF Collection: CSF was collected with a Sprotte 25-or 24-gauge spinal needle at the L3/4 or 
L4/5 using gentle extraction into polypropylene syringes. Samples were collected in the morning 
after a 12h fast. Approximately 22mL of CSF were inverted to avoid gradient, gently mixed and 
centrifuged at 2000g for 10 minutes. Supernatants were frozen in 0.5mL aliquots in 
polypropylene tubes and stored at −80°C.  
Plasma and CSF Markers of Inflammation: All plasma and CSF assays were conducted 
following the manufacturer's protocol for Human Chemokine Panel 1 V-PLEX Plus and Human 
Pro-Inflammatory Panel kits (Meso Scale Diagnostics, Rockville, MD). Each multiplex array was 
scanned using a MESO QuickPlex SQ 120. Manufacturer supplied software (Discover 
Workbench 4.0) was used to quantify the concentrations based on sample dilution and relative 
to the supplied in-assay standard curve. Nominal recovery for control levels remained between 
111%–120%. Standard curve coefficient of variation (CVs) for patient sample detection range 
remained <15% with standard sample recovery at 100% (+/− 5%) across all plates.  
CSF Biomarkers of AD Pathology and Neuronal Cell Damage: In terms of biomarkers of AD 
pathology (phosphorylated tau, P-Tau181 [p-tau]; Aβ42 and sAPPβ) and general markers of 
neuronal cell damage (total tau [T-Tau]; neurofilament light chain [NFL]), a subset of samples 
(n=147) were analyzed for p-tau, t-tau, Aβ42, and sAPPβ using commercially available enzyme-
linked immunosorbent assay (ELISA) methods (INNOTEST assays, Fujiurebio, Ghent Belgium) 
as described previously in detail23. CSF NFL was measured with a sandwich ELISA method 
(NF-light ELISA kit, UmanDiagnostics AB, Umeå, Sweden). Board-certified laboratory 
technicians who were blinded to clinical diagnosis performed all analyses on one occasion. All 
samples were analyzed according to protocols approved by the Swedish Board of Accreditation 
and Conformity Assessment (SWEDAC) using one batch of reagents (intra-assay coefficients of 
variation <10%). Three individuals had p-tau or t-tau levels below the detectible threshold of our 
assays, and those values were assigned the lowest detectible value for each marker (15.6 ng/L 
for p-tau; 75 ng/L for t-tau). 
Given that our primary study goal was to compare both CSF and plasma markers, we 
restricted the analysis to inflammatory markers wherein at least 70% data was available for both 
CSF and plasma, defined by detectability (within detection limits of assay) and CV’s (< or = 20% 
coefficient of variation). Although 20% is higher than classically defined 10% CV’s, we opted to 
be more inclusive in these analyses given that this is the first head-to-head comparison of a 
large number of CSF vs plasma inflammatory markers in asymptomatic aging adults. Note that 
results did not substantively change when we retrospectively restricted the analysis to 
individuals with 10% CV’s, although it did reduce the sample size. Using this data driven 
approach, five inflammatory markers met our criteria: MCP-1, MIP-1 beta, IP-10, IL-6 and IL-8 
(see Supplementary Table 1 and Supplementary Table 2 for quantification details).  
2.4 Statistical Analysis:  
Next, we faced a statistical modeling challenge as several of the analytes (MIP-1 beta, 
IP-10, IL-6 and IL-8) displayed isolated outliers. To reduce bias in our approach, we elected to 
remove outlier data points that were outside of 3 x the interquartile range (i.e. levels greater 
than Quartile 3 + [3*Interquartile Range] or Quartile 1 – [3*Interquartile Range]).  
 To examine the relationship between CSF and plasma levels of inflammation (Objective 
1), simple bivariate correlation analyses were first conducted, followed by linear regression 
models in which plasma inflammatory markers were entered as predictors in separate models, 
CSF markers of inflammation as the outcome variable, and age and sex as adjustment 
covariates. To determine whether CSF and plasma markers of inflammation independently 
predict CSF markers of AD pathology or neuronal cell damage (Objective 2), we next set up a 
series of separate general linear models. All models were adjusted for age and sex. CSF 
markers of AD pathology and neuronal cell damage were analyzed at two separate times (i.e. 
single time point data collection, two separate batches), thus we also included CSF batch as a 
covariate. We checked for collinearity between CSF and plasma markers of inflammation using 
standard techniques (e.g. variance inflation factor [VIF]), and VIF was less than 2 for all models. 
A natural log transformation was applied to NFL values to correct for a right skew. Separate 
linear models for the five inflammatory analytes were conducted with CSF and plasma levels 
entered simultaneously as predictors and CSF markers of AD pathology as separate outcome 
variables. This was repeated for indices of neuronal damage. We subsequently included APOE 
gene status to determine if the presence or absence of at least 1 E4 allele impacted the results. 
All analyses were conducted using SAS 9.4. 
3. Results 
3.1. Association Between Demographics, CSF and Plasma Inflammatory Markers  
 As noted in Table 1, the participant sample was comprised of middle aged to young 
older adults (mean age=63.9; SD=7.1) who were highly educated (mean education=16.3 years, 
SD=2.5) and predominantly female. The majority of individuals had a positive family history of 
Alzheimer’s disease (~70%), and APOE 4 status was overrepresented compared to the typical 
aging population (~36%).  
 As shown in Figure 1, the relationship between CSF and plasma levels of inflammation 
varied by individual marker; strong associations were noted between MIP-1β CSF and plasma 
levels (r=.55, p<.001), and modest associations between plasma and CSF levels were observed 
for IL-8 (r=.25, p=.001), IL-6 (r=.16, p=.05), MCP-1 (r=.28, p=.001) and IP-10 (r=.26, p=.001).  
 
 Age was associated with all inflammatory markers, with the exception of CSF IL-6 and 
plasma MIP-1β (p’s >.05; see Supplementary Figure 1). Neither education level nor family 
history of AD diagnosis was significantly associated with inflammatory markers, irrespective of 
specimen type (all p’s greater than .05). 
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Figure 1. Displays pearson correlations between plasma and CSF for each 
inflammatory marker. Bands represent a 95% confidence interval.based on 
Fisher's transformation.
3.2. Relationship of Inflammation and CSF Markers of AD Pathology: Head to Head 
Comparison of Plasma vs CSF Inflammation (Table 2) 
With respect to CSF markers of AD pathology, higher levels of IL-8 plasma and CSF (IL-
8 plasma: beta=2.17, 95% confidence interval [CI]=0.78 to 3.56; p=.002; IL-8 CSF: beta= 0.40, 
95%CI= 0.15 to 0.65; p=.002), MIP-1β CSF (beta=1.54, 95%CI= 0.52 to 2.56; p=.003), and IP-
10 CSF (beta=0.02, 95%CI= 0.01 to 0.04; p=.002) were associated with higher CSF p-tau levels 
in separate models for each marker. IL-8 CSF (beta=3.81; 95% CI= 0.73 to 6.89; p=.02) was the 
sole inflammatory markers associated with CSF Aβ42, such that higher levels of IL-8 CSF were 
unexpectedly associated with higher levels of CSF Aβ42. Finally, higher levels of IL-8 plasma 
(beta=23.47; 95%CI=6.07 to 40.87; p=.009) and MCP-1 plasma (beta=0.67; 95%CI=0.00 to 
1.34; p=.05) were associated with higher levels of CSF sAPP-β, but no associations were 
observed between CSF cytokines or chemokines and CSF sAPP-β.  
 
[Table 2] 
 
3.3. Relationship of Inflammation with CSF Markers of Neuronal Injury: Head to Head 
Comparison of Plasma vs CSF Inflammation (Table 3) 
In terms of markers of neuronal injury, higher IL-8 CSF and plasma levels (IL-8 plasma: 
beta= 13.97; 95%CI= 0.72 to 27.22; p=.04; CSF: beta= 3.53, 95%CI= 1.17 to 5.88; p=.004), IP-
10 CSF levels  (beta=0.18, 95%CI=0.05 to 0.30; p=.006), IL-6 plasma levels (beta=103.59; 
95%CI=11.80 to 195.38; p=.03), and MIP-1β CSF levels (beta=15.55; 95%CI= 6.15 to 24.95; 
p=.001) were associated with higher levels of total-tau. Higher levels of IP-10 plasma and CSF 
(IP-10 plasma, beta=0.0006; 95%CI= 0.0002 to 0.0009; p=.002; IP-10 CSF, beta=0.0004, 
95%CI=0.0001 to 0.0007, p=.008), IL-6 plasma (beta=0.251, 95% CI=0.05 to 0.46, p=.02), and 
IL-8 CSF (beta=0.01, 95%CI=0.00 to 0.01,p=0.003) were independently associated with higher 
CSF NFL levels.  
All results remained substantively unchanged when restricting the sample to clinical 
dementia rating (CDR) scale of 0 (removing 9 participants), with the exception of the 
relationship between IL-6 plasma and total tau; although the association remained in the same 
direction, the effect no longer reached statistical significance (p=.052). 
 
[Table 3] 
 
3.4 Exploratory Analyses: The Impact of CSF Aβ42 levels on the Relationship Between 
Inflammatory Markers and Tau Levels 
Standard biomarker analyses of AD pathology focus primarily on CSF levels of Aβ42, p-
tau, and total tau, and have been included in research criteria for preclinical AD24 and clinical 
diagnostic criteria for MCI and dementia due to AD25, 26. Based on both the utility of these 
markers in clinical diagnosis and current study results showing relatively larger effects of 
inflammatory markers on tau (p-tau; total tau) than Aβ42, we investigated whether lower Aβ42 
levels might alter the strength of the relationship between inflammatory markers and tau levels. 
This exploratory analysis thus addresses whether the relationship between higher inflammatory 
markers and higher tau markers of neuronal degeneration is more pronounced in the presence 
of increased amyloid deposition. In a series of linear models, we included an interaction term 
between CSF Aβ42 levels and individual inflammatory markers (plasma and CSF were 
evaluated in separate models, unlike analyses in section 3.3), with either CSF p-tau or CSF total 
tau as the primary outcome variables.  
With respect to p-tau, significant interactions between CSF Aβ42 and plasma IP-10 
(beta=-0.0001, SE=0.00004; t=-2.96; p=.004) as well as CSF Aβ42 and plasma MCP-1 (beta=-
0.0004; SE=0.0001; t=-3.15; p=.002) predicting CSF p-tau levels were noted. A trend for an 
interaction between CSF Aβ42 and CSF IL-8 (beta= -0.001; SE=0.0006; t=-1.90; p=.06),  
predicting p-tau levels was also observed. To visualize and further elucidate the interactions, we 
divided CSF Aβ42 into quartiles and plotted the relationship between each inflammatory marker 
and p-tau levels as a function of CSF Aβ42 quartiles (see Figure 2). Results were in the 
expected direction, such that stronger positive correlations between inflammatory markers and 
CSF p-tau were observed when CSF Aβ42 levels were lower. 
Analyses were repeated with total tau levels, and while all results were in the same 
direction as p-tau levels, effects for IP-10 plasma were smaller. Significant interactions were 
only noted between CSF Aβ42 and plasma MCP-1 (beta=-0.004, SE=0.001; t=-3.13; p=.002) 
predicting higher CSF total-tau levels. Trends for an interaction between CSF Aβ42 and plasma 
IP-10 (beta=-0.0007, SE=0.0004; t=-1.82; p=.07) and CSF Aβ42 and plasma CSF IL-8 were 
also observed (beta=-.009, SE=0.006; t=-1.70, p=.07). 
 
 
 Figure 2. Figure displays the association between inflammatory markers and p-tau levels as a function of 
CSF Aβ42 quartiles. P-tau levels were adjusted for demographics and APOE status. Significant 
interactions were observed for both plasma MCP-1 and plasma IP-10, such that stronger positive 
correlations between inflammatory markers and CSF p-tau were observed when CSF Aβ42 levels were 
lower. 
4. Discussion 
In a cohort of asymptomatic older adults enriched for a family history of Alzheimer’s 
disease, we found modest associations between plasma and CSF levels of inflammation, 
although the relationship between plasma and CSF MIP-1β was quite strong. Importantly, 
results indicate that plasma and CSF markers of inflammation may relay independent and 
distinct information about AD pathology and neuronal damage in the absence of clinical 
symptoms. These findings collectively suggest that innate immune system dysregulation may be 
an early event in the AD pathogenic course, and that inflammation may be particularly 
deleterious in the presence of Aβ42 deposition. 
A systemic inflammatory response has been reported in both aging27, 28 and AD29-32, 
although the utility of plasma inflammation as an indicator of CNS immune dysregulation has 
been more controversial and remarkably understudied. One of the two primary goals of our 
study was to assess the association between CSF and plasma inflammation to clarify how well 
plasma inflammation reflects CNS inflammation.  The correlations between CSF and plasma for 
several inflammatory analytes (MCP-1, IL-6, IL-8, and IP-10) were suggestive of small to 
medium effects, whereas the relationship between CSF and plasma MIP-1β was notable for 
larger effects (r=.55). These results indicate that the level of correspondence between CSF and 
plasma may vary as a function of the specific analyte, although it’s unclear whether the strength 
of associations between CSF and plasma inflammation equate to more adverse clinical 
outcomes. Moreover, these results raise questions regarding the structural integrity of CNS-
periphery boundaries, and whether specific inflammatory markers have varying degrees of 
permeability throughout the disease process.  
In line with these questions, connections between the CNS and periphery in the context 
of aging and AD have stirred numerous debates, although it’s clear that CSF spaces (i.e. 
subarachnoid space and ventricles) do not display the same level of immune privilege as the 
parenchyma21. Moreover, the choroid plexus, which serves as a blood-CSF barrier (BCSFB) in 
addition to its role in CSF production, has been shown to conduct immunosurveillance and 
interface between the CNS and peripheral circulation18. Under physiological (i.e. non-
pathological) conditions, the choroid plexus maintains tight junctions that prevent the passage of 
myeloid immune cells into the CNS; however, recent reports suggest that the BCSFB 
undergoes structural and functional alterations in the presence of33 and possibly preceding19 
amyloid deposition. These alterations may have downstream effects on CSF-interstitial fluid 
exchange that could ultimately impact communication with the periphery34. Chemokines in 
particular may play a critical role in uni-directional or bi-directional communication between the 
CNS and periphery early on in the disease course.  Prior studies have suggested that several 
markers from the CC and CXCL chemokine families are upregulated and expressed in the 
CSF35 and plasma36 in the context of aging. Moreover, blood-borne chemokines have also been 
shown to induce alterations in the CNS in animal models, including declines in hippocampal 
neurogenesis and impairments in memory function36, 37. Although evidence suggests that 
immune communication between the CNS and periphery is not only possible, but likely in 
pathological states, this does not resolve why isolated chemokines (MIP-1β) showed stronger 
associations between CSF and plasma than other inflammatory markers in our study, nor does 
it address the directionality of CNS-peripheral communication with respect to inflammation as a 
whole. Despite these unanswered questions, our results do point to some degree of overlap 
between CSF and plasma inflammation that should be explored further in future studies. 
Directly relevant to the role of blood inflammation as an indicator of the CNS milieu is the 
extent to which CSF and plasma inflammatory levels independently predict biomarkers of AD 
pathology and neuronal cell damage. We initially hypothesized that if plasma inflammation was 
a downstream indicator of CNS alterations that it might not contribute unique variance to 
markers of neuronal integrity or AD pathology when compared to CSF. More specifically, given 
that CSF is thought to be a more proximal indicator of the CNS milieu, one might expect that 
CSF markers of inflammation would be stronger predictors of AD pathology and neuronal cell 
damage than plasma markers of inflammation. Results from our study suggest that both plasma 
and CSF markers of inflammation independently relay information about AD pathology and 
neuronal damage in head-to-head comparisons.  With respect to indices of AD pathology (i.e. 
markers of amyloid deposition and phosphorylated tau), higher plasma and CSF levels of IL-8 
were associated with higher levels of CSF p-tau, and higher levels of IL-8 were also associated 
with higher levels of CSF-Aβ42 (CSF only) and CSF-sAPPβ (plasma only). Interestingly, IL-8 
was the only marker associated with Aβ42 levels, and was in a counterintuitive direction. Recent 
evidence from transgenic mice suggests that there may be a temporary increase in CSF Aβ42 
levels prior to a precipitous decline38, thus it is possible that this association reflects a very early 
alteration in the pathological cascade. Of note, higher levels of CSF IP-10 and CSF MIP-1β 
were also associated with higher CSF p-tau levels, again reiterating the potential role of 
chemokines in early stages of AD pathogenesis39.   
With respect to indices of general neuronal damage (total tau; NFL), we found 
independent associations between higher levels of CSF (IL-8, IP-10, and MIP-1β) and plasma 
(IL-6; IL-8) inflammation and higher levels of CSF total tau, as well as higher levels of plasma 
(IP-10; IL-6) and CSF (IP-10; IL-8) inflammation and higher levels of NFL. Overall, markers of 
inflammation displayed particularly consistent associations with levels of tau (p-tau and total tau) 
and NFL that were generally stronger than associations with Aβ42 levels, highlighting a potential 
role for both CSF and plasma inflammation as markers of underlying neuronal damage. 
Whether these associations suggest a specific relationship with neuronal damage in AD 
remains unclear. To clarify, whereas total tau and NFL reflect general markers of neuronal 
damage that have been associated with microglial alterations and inflammation in the context of 
a wide range of neurodegenerative diseases40, 41, phosphorylated tau is a marker of neuronal 
damage that is specifically linked with AD pathology. Despite this distinction, they are all 
typically elevated in the CSF of AD and may be indicators of general disease progression or 
severity. Potentially consistent with our study findings, recent animal studies have uncovered a 
strong relationship between systemic inflammation and tau propagation. One of the earliest 
studies on this relationship found that secretion of the cytokine IL-1β from microglia was 
sufficient to increase tau phosphorylation in culture42. More recent studies have further 
demonstrated that dysregulated immune processes, including reactive microglia and altered 
chemokine receptors, precede and exacerbate phosphorylated tau aggregation in mouse 
models of AD43, 44. Thus, whereas the differential role of CSF versus plasma inflammation in 
predicting AD pathogenesis and progression remains unclear, the bourgeoning literature on tau 
propagation in tandem with our study results suggest that both central and systemic 
inflammation may contribute to the development of AD-specific tau pathology and impact 
neuronal integrity in aging adults.  
Following up on our study results suggesting that CSF and plasma inflammation may 
reflect evidence of neuronal damage, we also explored whether the relationship between 
inflammatory markers and tau levels was impacted by the presence of Aβ42. We focused our 
analyses primarily on p-tau and total tau given their respective roles in current diagnostic 
guidelines for AD, although it is notable that associations with NFL were also quite strong. A 
significant interaction was observed between CSF Aβ42 levels and both plasma MCP-1 and 
plasma IP-10, such that the associations between higher levels of inflammation and higher 
levels of p-tau were stronger when CSF Aβ42 levels were lower. Similar patterns of associations 
were noted for total tau, although the effect sizes were notably smaller for the IP-10 x Aβ42 
interaction. These findings suggest that the impact of pro-inflammatory cascades on neuronal 
integrity may be contingent upon the degree of amyloid deposition in the brain; however, it’s 
important to highlight that in the context of a cross-sectional design, these findings may be 
interpreted in several ways, and thus warrant consideration of current theoretical frameworks. 
Recent literature suggests that inflammatory markers play an early pathogenic role in AD 
development45, such that the presence of Aβ primes microglia and elicits the production of 
inflammatory mediators. In the context of chronic activation, microglia and astrocytes undergo 
morphological changes that can result in dysregulation of inflammatory feedback loops and 
reduction in critical trophic factors1. These dynamic alterations may aggravate tau propagation 
and ultimately lead to neuronal death. Thus, one interpretation of the literature and current data 
is that the temporal lag between Aβ deposition and clinical outcomes is in part driven by both a 
central and systemic dysregulation of the inflammatory response that occurs only after a critical 
threshold of amyloid deposition is reached.  An additional consideration of the current data is 
that it may provide insight into the discordant literature on blood inflammation and clinical 
outcomes in typical aging studies4, 46-48, as it may be that stronger associations between 
inflammation and aging variables are evident primarily in individuals with higher Aβ deposition.  
In terms of study limitations and confines to interpretation, we utilized a data-driven 
approach to identify inflammatory markers of interest; although this permitted us to perform 
head-to-head analyses, it also limited our ability to address potentially important markers that 
were detectable in one specimen type only. In addition, although CSF markers of AD pathology 
and neuronal integrity are considered a gold standard for diagnosis of preclinical and clinical 
AD, we also faced a potential bias in head-to-head comparisons, as CSF-CSF comparisons 
might be artificially stronger than plasma-CSF associations due to continuity in methods. 
Nonetheless, the independent effects of both plasma and CSF inflammation in the context of 
these methods are encouraging. An additional consideration is that we used CSF levels as a 
proxy for the CNS milieu; however, there are still boundaries between the CSF and parenchyma 
(e.g. ependymal cell layers) that provide immunological privilege, thus it’s important to consider 
that CSF may not encapsulate the complexity of AD pathogenic processes in the CNS.  Finally, 
as noted previously, although we have offered speculations as to potential mechanisms and 
points of interaction between the CNS and periphery, the cross-sectional design of the current 
study limits our ability to address directionality of communication between the nervous systems 
or causality with respect to the immune response. In order to disentangle the roles of CSF and 
plasma inflammation in the context of AD, longitudinal studies that include both pre-clinical and 
early AD (i.e. MCI due to AD) will be necessary. 
In summary, in a cohort of asymptomic aging adults enriched for a family history of AD, 
modest associations were observed between plasma and CSF levels of inflammation, and 
results suggest that both plasma and CSF markers of inflammation independently relay integral 
information about AD pathology and neuronal damage. Results support a potential role for 
inflammatory cascades early in the AD pathogenic progress, prior to clinical manifestation of 
disease, and highlight that inflammation may be particularly deleterious in the presence of Aβ42 
deposition. These findings add to a growing body of literature underscoring a complex 
relationship between systemic inflammation, central inflammation, and pathological outcomes. 
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